1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 study
Matteo S Carlino(Melanoma Institute Australia), Bella Nguyen(Salk Institute for Biological Studies), Ann W. Silk(Dana-Farber Cancer Institute), Jameel Muzaffar(Moffitt Cancer Center), Roman Groisberg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wilson H. Miller(Jewish General Hospital), Leah Suttner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vincent Castonguay(Centre hospitalier universitaire de Québec), Alex Gozman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jia Liu(Sun Yat-sen University), Omer Dizdar(Hacettepe University Hospital), Aarti Bhatia(Yale Cancer Center), Shlomo A. Koyfman(Cleveland Clinic)
Cited by 0
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
|Current Oncology|2020|941
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
|Molecular Cancer|2019|549
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
|Cell Systems|2018|452
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
|Nature Medicine|2023|446